Ana Leticia Maragno

This inventor holds 5 USPTO granted patents and 8 published patent applications, plus 5 CIPO patents and 6 EPO patents. Top assignees: Les Laboratoires Servier, Novartis Ag, Vernalis (R&D) Ltd. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ana Leticia Maragno. Retrieved from https://idiyas.com/inventor/ana-leticia-maragno

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 (Patent Applications = 8)

% Patents Active = 100.0

CIPO Patents = 5 (Patent Applications = 9)

EPO Patents = 6 (Patent Applications = 11)

Average Co-Inventor Count = 9.9

ph-index = 1

Forward Citations = 1(Granted Patents)

Company Filing History:

4 out of 296

Les Laboratoires Servier

Les Laboratories Servier

where one patent can have more than one assignee

Years Active: 2019-2026

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12649733 - 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS (2026-06-09),

2. 12570648 - 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER (2026-03-10),

3. 11466023 - Combination of a Mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof (2022-10-11),

4. 10765680 - Combination of a MCL-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof (2020-09-08),

5. 10457689 - Ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them (2019-10-29),

Title: Ana Leticia Maragno: Innovator in Hematologic Cancer Treatments

Introduction

Ana Leticia Maragno is a prominent inventor based in Croissy sur Seine, France. She has made significant contributions to the field of oncology, particularly in the development of innovative treatments for hematologic cancers. With a total of 5 patents to her name, her work is paving the way for new therapeutic options.

Latest Patents

Maragno's latest patents include groundbreaking combinations aimed at enhancing cancer treatment efficacy. One notable patent is for a combination of a Mcl-1 inhibitor and a standard of care treatment for hematologic cancers. This patent details the uses and pharmaceutical compositions of a combination that includes a Mcl-1 inhibitor and a second anticancer agent, selected from anthracyclines, cytarabine, and hypomethylating agents. Another significant patent involves a combination of a MCL-1 inhibitor and a taxane compound, which also outlines the compositions and uses thereof.

Career Highlights

Throughout her career, Ana Leticia Maragno has worked with esteemed companies such as Les Laboratoires Servier and Novartis AG. Her experience in these organizations has allowed her to collaborate on various innovative projects that aim to improve cancer treatment outcomes.

Collaborations

Maragno has collaborated with notable professionals in her field, including Olivier Geneste and Maïa Chanrion. These partnerships have contributed to her success and the advancement of her research.

Conclusion

Ana Leticia Maragno is a trailblazer in the field of cancer treatment, with her innovative patents and collaborations marking her as a key figure in oncology research. Her work continues to inspire advancements in therapeutic strategies for hematologic cancers.

Profile summary based on public USPTO records.